Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 3, 2011, Pages 456-460

  Liu, Feng ^a,b   Wang, Lei ^a   Li, Xiao Ying ^c   Liu, You De ^d   Wang, Jing Bo ^c   Zhang, Zhao Hua ^c   Wang, Yao Zong ^c  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c JINAN INFECTIOUS DISEASE HOSPITAL   (China)

^d Yantai Infectious Disease Hospital   (China)

Author keywords

Chronic drug therapy; Hepatitis B; Hepatitis B e Antigen negative; Lamivudine therapeutic use; Prospective studies; Recurrence relapse

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE;

EID: 79951623871     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06492.x     Document Type: Article

References (21)

1. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-63.
2. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J. Hepatol. 2000; 33: 301-7.
3. Schiff ER, Dienstag JL, Karayalcin S etal. Lamivudine and 24weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J. Hepatol. 2003; 38: 818-26.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
5. Kobayashi M, Suzuki F, Akuta N etal. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J. Med. Virol. 2007; 79: 1472-7.
6. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-83.
7. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. J. Infect. Dis. 1997; 175: 1285-93.
8. Myers R, Clark C, Khan A etal. Genotyping Hepatitis B virus from whole- and sub-genomic fragments using position-specific scoring matrices in HBV STAR. J. Gen. Virol. 2006; 87: 1459-64.
9. Rozanov M, Plikat U, Chappey C etal. A web-based genotyping resource for viral sequences. Nucleic Acids Res. 2004; 32: 654-9.
10. Fung SK, Wong F, Hussain M etal. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J. Viral Hepat. 2004; 11: 432-8.
11. Huang YH, Wu JC, Chang TT etal. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J. Viral Hepat. 2003; 10: 277-84.
12. Wang L, Liu F, Liu YD etal. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J. Viral Hepat. 2010; 17: 298-304.
13. Song BC, Suh DJ, Lee HC etal. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
14. Lee HC, Suh DJ, Ryu SH etal. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003; 52: 1779-83.
15. Chien RN, Yeh CT, Tsai SL etal. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-73.
16. Zeuzem S, Honkoop P, Roth WK. Dynamics of hepatitis B virus infection in vivo. J. Hepatol. 1997; 27: 431-6.
17. Mason WS, Cullen J, Moraleda G etal. Lamivudine therapy of WHV-infected woodchucks. Virology. 1998; 245: 18-32.
18. Chang TT, Lai CL, Chien RN etal. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2004; 19: 1276-82.
19. Shin JW, Park NH, Park JH etal. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B. J. Viral Hepat. 2005; 12: 393-7.
20. Ryu SH, Chung YH, Choi MH etal. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J. Hepatol. 2003; 39: 614-19.
21. Zeng G, Wang Z, Wen S etal. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J. Viral Hepat. 2005; 12: 609-17.